Botulinum neurotoxins for post-stroke spasticity in adults: A systematic review

Movement Disorders

Volumn 24, Issue 6, 2009, Pages 801-812

  Elia, Antonio Emanuele ^a,b   Filippini, Graziella ^a   Calandrella, Daniela ^a,b   Albanese, Alberto ^a,b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

Botulinum toxin; Metaanalysis; Spasticity; Stroke

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ARM PAIN; ARTHRALGIA; ASTHENIA; BRAIN FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COORDINATION DISORDER; DEPRESSION; DISABILITY; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPHAGIA; ECCHYMOSIS; ELECTROSTIMULATION; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; GAIT DISORDER; GENETIC HETEROGENEITY; HIP PAIN; HUMAN; HYPERTENSION; HYPESTHESIA; HYPOTHYROIDISM; JOINT SPASTICITY; LOWER LIMB SPASTICITY; LUNG FUNCTION; LYMPHOMA; MOTOR PERFORMANCE; MUSCLE SPASM; MYALGIA; OUTCOME ASSESSMENT; PAIN; PERIPHERAL EDEMA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; REVIEW; RISK REDUCTION; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPASTICITY; STROKE; SYSTEMATIC REVIEW; THERAPY EFFECT; UPPER LIMB SPASTICITY; URINARY TRACT INFECTION; VISCERAL LYMPHOMA; WEAKNESS; XEROSTOMIA;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; HUMANS; MUSCLE SPASTICITY; STROKE;

EID: 67651159120     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22452     Document Type: Review

References (47)

1. Mayer NH, Esquenazi A. Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys Med Rehabil Clin N Am 2003;14:855-883.
2. Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg lecture. Neurology 1980;30:1303-1313.
3. Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol 2001;14: 771-776.
4. Esquenazi A. Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. Eur J Neurol 2006;13 (Suppl 4):27-34.
5. Woldag H, Hummelsheim H. Is the reduction of spasticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients? Eur Neurol 2003;50:165-171.
6. Platz T, Eickhof C, Nuyens G, Vuadens P. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil 2005;27:7-18.
7. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
8. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-542.
9. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-207.
10. Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004;85:1063-1069.
11. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-221.
12. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers' product summaries. J Clin Pharm Ther 2007;32:387-402.
13. Cochrane Handbook for Systematic Reviews of Interventions. 2007. (Internet communication).
14. Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002;7:51-61.
15. On AY, Kirazli Y, Kismali B, Aksit R. Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow-up. Am J Phys Med Rehabil 1999;78:344-349.
16. Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil 1998;77:510-515.
17. Verplancke D, Snape S, Salisbury CF, Jones PW, Ward AB. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005;19:117-125.
18. Richardson D, Sheean G, Werring D, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000;69:499-506.
19. Burbaud P, Wiart L, Dubos JL, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265-269.
20. O'Brien CF, Simpson DM, Alexander DN, Tagliati M, Aswad AS, Gibson J. A randomized, doubleblind, placebo-controlled study to evaluate the use of botulinum toxin type A in the treatment of spasticity. Neurology 1995;45(4 Suppl 4):A329.
21. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46: 1306-1310.
22. Childers MK, Brashear A, Jozefczyk PB, Reding MJ, Dru RM, Lee CH. A multicenter, double-blind, placebo-controlled dose response trial of botulinum toxin type A (Botox®) in upper limb spasticity poststroke. Neurology 1999;52(6 Suppl 2):A295.
23. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil 1998;12:381-388.
24. Smith SJ, Ellis E, White S, Moore AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5-13.
25. Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, doubleblind, placebo-controlled, dose-ranging study to compare the ef.cacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-2406.
26. Bakheit AM, Pittock S, Moore AP, et al. A randomized, doubleblind, placebo-controlled study of the ef.cacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8:559-565.
27. Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003;15:289-300.
28. Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004;85:705-709.
29. Suputtitada A, Suwanwela NC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 2005;27:176-184.
30. Albanese A, Bentivoglio AR. Botulinum toxin in movement disorders. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. pp 605-619.
31. Cardoso E, Rodrigues B, Lucena R, Oliveira IR, Pedreira G, Melo A. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arq Neuropsiquiatr 2005;63:30-33.
32. Sheean G. Botulinum toxin treatment of adult spasticity: a benefit- risk assessment. Drug Saf 2006;29:31-48.
33. Simpson DM, Gracies JM, Graham HK, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidencebased review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-1698.
34. Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H. A review of the properties and limitations of the Ashworth and modi.ed Ashworth Scales as measures of spasticity. Clin Rehabil 1999;13:373-383.
35. Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ. Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 2006;21:1737-1741.
36. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration, International Stroke Incidence Collaboration. Stroke 1997;28:491-499.
37. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40:277-280.
38. Bentivoglio AR, Albanese A. Botulinum toxin in motor disorders. Curr Opin Neurol 1999;12:447-456.
39. Bakheit AM, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004;75:1558-1561.
40. U.S.Food and Drug Administration. Early communication about an ongoing safety review Botox and Botox Cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B). 2008 (Internet Communication).
41. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003;4: CD001332.
42. Wasiak J, Hoare B, Wallen M. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev 2004;4: CD003469.
43. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004; 20:981-990.
44. Turkel CC, Bowen B, Liu J, Brin MF. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil 2006;87:786-792.
45. Dressler D, Eleopra R. Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res 2006;9:121-125.
46. Ward AB. A summary of spasticity management - a treatment algorithm. Eur J Neurol 2002;9 (Suppl. 1):48-52.
47. Outpatient Service Trialists. Therapy-based rehabilitation services for stroke patients at home. Cochrane Database Syst Rev 2003; 1:CD002925.